Will Regeneron Close At $400?

8/23/18

By Chris Lau, SeekingAlpha

Summary

Shares of Regeneron closed at my target price after reporting a solid second quarter.

Company is suitable for long-term investors only.

Does REGN's stock deserve a big premium over comparable biotech stocks?

Members of our private investing community, DIY Value Investing, get exclusive access to ideas like this one. Get started today >>

When Regeneron Pharmaceuticals (REGN) reported strong second-quarter earnings earlier this month, the stock soared to around my 30 percent upside target. Now that it met the market's expectations, what upside remains? The stock topped $397 on August 2 and began a descent to around $362 on August 15 before settling slightly higher. At a 27 times P/E, investors need to decide if the stock deserves this multiple after reporting a 9.5 percent year-over-year revenue growth.

For those unfamiliar with Regeneron, the company has a partnership with Sanofi (SNY) for developing Dupixent. This drug treats severe atopic dermatitis and the company has yet to address much of the market. Since it is an early player in the market, the company has a good chance of rapidly growing market share in the quarters and years ahead.

READ FULL ARTICLE HERE